Despite these limitations, the inhibition of CD47 in human tumor xenografts has proven to be effective, impairing the growth of lymphoma, leukemia, glioblastoma, breast, colon, ovarian, and lung cancer models [244,249]. Here, CD47 is linked to lymphoma.